Nasdaq:CRON
Cronos Group Inc.
A vertically integrated cannabis leader delivering premium consumer goods across North American recreational and medical markets with a strong cash position.
Key Metrics
Investment Thesis
Bull Case
Cronos Group is well-positioned to capitalize on the long-term secular growth of the cannabis industry as market consolidation accelerates and barriers to entry rise for smaller players. The company's diversified product portfolio and strong brand equity offer a defensive moat in an evolving sector with expanding addressable markets. Significant cash reserves provide the financial stability needed to execute strategic M&A targets and invest in R&D without immediate pressure from quarterly earnings.
Bear Case
The company's recent net income volatility, including losses in 2022 and 2023, suggests ongoing profitability challenges that investors should monitor closely as they scale operations. Regulatory headwinds remain a persistent threat, with potential changes in tax policies or licensing requirements capable of materially impacting future cash flows. High capital expenditures of $25.7M in the latest period combined with negative free cash flow dynamics may constrain returns on invested capital in the near term.
About Cronos Group Inc.
Cronos Group Inc. is a leading North American manufacturer of cannabis-infused consumer goods, operating primarily in the recreational and medical markets across Canada and the United States. The company specializes in producing premium edibles, beverages, topicals, and other lifestyle products under its diverse portfolio of brands. Cronos leverages a vertically integrated supply chain to deliver high-quality, compliant products to retail partners and direct-to-consumer channels.
Analysis
Management Discussion
In 2025, Cronos Group reported revenue of $146.6M, a significant increase from the previous year's $117.6M, indicating successful market penetration and operational scaling. However, the company posted a net loss of $-2.9M for the period, with operating profit at $-17.4M, reflecting continued investment in growth initiatives and capacity expansion despite strong top-line performance. Cash flow from operations was positive at $25.9M, providing a buffer against the reported net loss and financing outflows.
Industry Overview
The global cannabis industry is experiencing rapid growth driven by increasing legalization trends and shifting consumer attitudes toward medicinal and recreational use. Market consolidation is underway as smaller operators struggle with compliance costs, creating opportunities for established players like Cronos to acquire assets and market share. Technological advancements in extraction and formulation are enabling more diverse product offerings that appeal to mainstream consumers beyond traditional medical users.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $91.9M | $87.2M | $117.6M | $146.6M |
| Cost of Revenue | $79.9M | $75.3M | $92.4M | $83.8M |
| Gross Profit | $12.0M | $11.9M | $25.2M | $62.8M |
| Operating Expenses | $136.8M | $96.7M | $101.7M | $80.2M |
| Operating Income | $-124.8M | $-84.8M | $-76.5M | $-17.4M |
| R&D | $13.4M | $5.8M | $4.2M | $4.4M |
| G&A | $71.2M | $49.5M | $46.5M | $42.0M |
| Marketing | $22.3M | $22.7M | $21.6M | $21.8M |
| Stock-Based Comp | $15.1M | $8.8M | $8.7M | $7.0M |
| D&A | $13.1M | $8.1M | $9.3M | $14.2M |
| Amortization | $2.8M | $3.5M | — | — |
| Other OpEx | $30.0M | $18.7M | $29.4M | $11.9M |
| Non-Operating Income | $-9.7M | $11.1M | $113.1M | $275.0K |
| Interest Expense | $13.0K | — | — | — |
| Interest Income | $22.6M | — | — | — |
| Pre-Tax Income | $-134.6M | $-73.7M | $36.6M | $-17.1M |
| Income Tax | $34.2M | $-3.2M | $-3.4M | $-14.2M |
| Continuing Ops | $-168.7M | $-70.4M | $40.0M | $-2.9M |
| Discontinued Ops | $0 | $-4.1M | $0 | $0 |
| Net Income | $-168.7M | $-74.6M | $40.0M | $-2.9M |
| Minority Interest | $0 | $-590.0K | $-1.1M | $6.5M |
| Net to Common | $-168.7M | $-74.0M | $41.1M | $-9.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $960.2M | $933.3M | $936.1M | $944.1M |
| Cash & Equivalents | $764.6M | $669.3M | $858.8M | $791.8M |
| Marketable Securities | $113.1M | $192.2M | $0 | $40.0M |
| Accounts Receivable | $23.1M | $14.0M | $15.5M | $34.1M |
| Inventory | $37.6M | $30.5M | $33.1M | $46.8M |
| Prepaid Expenses | $7.1M | $5.4M | $6.3M | $8.3M |
| Other Current Assets | $14.7M | $21.9M | $22.4M | $23.1M |
| Long-Term Assets | $252.9M | $206.8M | $230.2M | $253.1M |
| PP&E (Net) | $60.6M | $59.5M | $133.2M | $145.9M |
| Intangibles | $26.7M | $21.1M | $11.3M | $8.9M |
| Goodwill | $1.0M | $1.1M | $63.5M | $66.5M |
| Operating Leases | $2.3M | $1.4M | $1.4M | $1.4M |
| Other LT Assets | $143.5M | $104.3M | $20.9M | $30.4M |
| Total Assets | $1.21B | $1.14B | $1.17B | $1.20B |
| Current Liabilities | $68.1M | $41.4M | $49.7M | $48.2M |
| Accounts Payable | $11.2M | $12.1M | $17.0M | $11.6M |
| Current Leases | $1.3M | $994.0K | $1.0M | $337.0K |
| Taxes Payable | $33.0M | $64.0K | $9.0K | $0 |
| Other Current Liab | $399.0K | $475.0K | $40.0K | $0 |
| Long-Term Liabilities | $3.9M | $2.6M | $5.6M | $6.0M |
| LT Operating Leases | $2.5M | $1.6M | $993.0K | $1.2M |
| Other LT Liab | $1.4M | $1.0M | $4.6M | $4.8M |
| Total Liabilities | $72.0M | $44.0M | $55.3M | $54.2M |
| Shareholders' Equity | $1.14B | $1.10B | $1.11B | $1.14B |
| Paid-In Capital | $42.7M | $48.4M | — | — |
| Retained Earnings | $490.7M | $416.7M | $457.7M | $447.8M |
| AOCI | $-797.0K | $20.7M | $-63.5M | $-16.8M |
| Total L&E | $1.21B | $1.14B | $1.17B | $1.20B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-168.7M | $-74.6M | $40.0M | $-2.9M |
| Non-Cash Adjustments | $39.6M | $62.7M | $-12.1M | $-12.7M |
| Working Capital Changes | $40.2M | $-31.0M | $-9.1M | $41.5M |
| Cash from Operations | $-88.9M | $-42.8M | $18.8M | $25.9M |
| Capital Expenditures | $3.5M | $2.5M | $12.4M | $25.7M |
| Cash from Investing | $-1.8M | $-59.5M | $175.1M | $-76.6M |
| Share Buybacks | — | — | — | $9.7M |
| Cash from Financing | $-2.9M | $-1.0M | $-1.2M | $-19.9M |
| FX Effect | $-28.6M | $8.0M | $-3.2M | $3.6M |
| Net Change in Cash | $-122.3M | $-95.4M | $189.5M | $-67.0M |
| Beginning Cash | $887.0M | $764.6M | $669.3M | $858.8M |
| Ending Cash | $764.6M | $669.3M | $858.8M | $791.8M |
Frequently Asked Questions
How does Cronos Group Inc. make money?
Cronos Group operates through its core Cannabis segment which encompasses the manufacturing and distribution of edible gummies, beverages, topicals, and other infused products for both adult-use and medical patients. Revenue is generated from wholesale partnerships with major retailers as well as direct-to-consumer sales via its e-commerce platform and branded retail locations.
What are the main risks for CRON?
Ongoing regulatory uncertainty and the potential for stricter enforcement or changing laws in key markets like Canada and the United States could disrupt operations and revenue streams. Intense competition from large pharmaceutical giants and other established cannabis players may lead to price wars that erode gross margins. The company faces execution risks related to scaling production capacity efficiently without compromising product quality as it expands into new territories.
What is CRON's competitive advantage?
Cronos Group maintains a vertically integrated supply chain that secures access to high-quality raw materials while controlling production costs from cultivation through distribution. The company has established a robust brand portfolio recognized for quality and consistency in a rapidly consolidating market, allowing it to command premium pricing power. Strong balance sheet liquidity provides significant flexibility for strategic acquisitions and navigating regulatory complexities in new jurisdictions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.